Disease · MONDO_0002974
cervical cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cervical cancer. Diseases, record MONDO_0002974. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002974
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of uterine cervix, cervical cancer, somatic, malignant cervical neoplasm, malignant cervical tumor, malignant cervical tumour, malignant cervix neoplasm, malignant cervix tumor, malignant cervix tumour, malignant cervix uteri neoplasm, malignant cervix uteri tumor, malignant cervix uteri tumour, malignant neoplasm of cervix, malignant neoplasm of cervix uteri, malignant neoplasm of the cervix, malignant neoplasm of the cervix uteri, malignant neoplasm of the uterine cervix, malignant neoplasm of uterine cervix, malignant tumor of cervix, malignant tumor of cervix uteri, malignant tumor of the cervix, malignant tumor of the cervix uteri, malignant tumor of the uterine cervix, malignant tumor of uterine cervix, malignant tumour of cervix, malignant tumour of cervix uteri, malignant tumour of the cervix, malignant tumour of the cervix uteri, malignant tumour of the uterine cervix, malignant tumour of uterine cervix, malignant uterine cervix neoplasm, malignant uterine cervix tumor, malignant uterine cervix tumour, uterine cervix cancer
- Open Targets
- Highest stage of its drugs
- Approval, for 6 of its 232 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs232
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Approval | DailyMed and EMA Human Drugs | 44 | 33 | 33 | Drugs and targets |
| TOPOTECAN | CHEMBL84 | Small molecule | Approval | EMA Human Drugs | 16 | 11 | 11 | Drugs and targets |
| TISOTUMAB VEDOTIN | CHEMBL4297841 | Antibody drug conjugate | Approval | EMA Human Drugs, FDA, PMDA and TTD | 9 | 5 | 5 | Drugs and targets |
| CEMIPLIMAB | CHEMBL4297723 | Antibody | Approval | PMDA | 4 | 3 | 3 | Drugs and targets |
| ABOBOTULINUMTOXINA | CHEMBL2108570 | Approval | TTD | 1 | 0 | 0 | Drugs and targets | |
| INCOBOTULINUMTOXINA | CHEMBL2108035 | Approval | TTD | 1 | 0 | 0 | Drugs and targets | |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 178 | 178 | 178 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 108 | 108 | 104 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 71 | 71 | 71 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 39 | 39 | 39 | Drugs and targets |
1 to 10 of 232
See all 232 drugsTargets259
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 15 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 14 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 12 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| TUBA1A | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor | Approval | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 259
See all 259 targetsTrials500
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | Phase 3 | 1,060 | 2026-01-05 | Uterine Cervical Neoplasms | CISPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01414608 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | Phase 3 | 926 | 2022-11-07 | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7 | CARBOPLATIN, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) | Phase 3 | 770 | 2023-03-06 | Locally Advanced Cervical Cancer | CARBOPLATIN, CISPLATIN, DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | Phase 3 | 617 | 2023-10-12 | Cervical Cancer | CARBOPLATIN, CISPLATIN, PACLITAXEL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03257267 | Study of Cemiplimab in Adults With Cervical Cancer | Phase 3 | 608 | 2022-04-06 | Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer | CEMIPLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | Phase 1/2 | 578 | 2022-04-12 | Various Advanced Cancer | DARATUMUMAB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase 1/2 | 515 | 2021-04-06 | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | SACITUZUMAB GOVITECAN | Its record names the disease | ClinicalTrials.gov |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | Phase 3 | 502 | 2024-08-09 | Cervical Cancer | GEMCITABINE, IRINOTECAN, PEMETREXED, TISOTUMAB VEDOTIN, TOPOTECAN, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | Phase 3 | 452 | 2016-05-24 | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer | BEVACIZUMAB, CISPLATIN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Phase 3 | 450 | 2024-01-05 | Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | CISPLATIN, TRIAPINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 500
See all 500 trialsComparisons in its trials68
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + CCRT vs Placebo + CCRT: deaths from any cause | 107 of 529 | 140 of 531 | 1,060 | NCT04221945 | Trial comparisons |
| Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab: Number of Participants Who Experience One or More Adverse Events (AEs) | 528 of 528 | 526 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab: Number of Participants Who Discontinue Study Treatment Due to an AE | 112 of 528 | 79 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Pembrolizumab + CCRT vs Placebo + CCRT: serious adverse events | 175 of 528 | 153 of 530 | 1,058 | NCT04221945 | Trial comparisons |
| Standard Chemoradiation vs Standard Chemoradiation With Adjuvant Chemotherapy: deaths from any cause | 123 of 456 | 109 of 463 | 919 | NCT01414608 | Trial comparisons |
| Standard Chemoradiation vs Standard Chemoradiation With Adjuvant Chemotherapy: serious adverse events | 98 of 453 | 107 of 361 | 814 | NCT01414608 | Trial comparisons |
| Durva + SoC CCRT vs Placebo + SoC CCRT: deaths from any cause | 91 of 385 | 112 of 385 | 770 | NCT03830866 | Trial comparisons |
| Durva + SoC CCRT vs Placebo + SoC CCRT: serious adverse events | 113 of 385 | 90 of 384 | 769 | NCT03830866 | Trial comparisons |
| Cemiplimab vs Investigator Choice (IC) Chemotherapy: Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1 | 52 of 304 | 19 of 304 | 608 | NCT03257267 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: deaths from any cause | 123 of 253 | 140 of 249 | 502 | NCT04697628 | Trial comparisons |
1 to 10 of 68
See all 68 comparisons in its trialsPapers from its trials283
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002974
GET https://conductscience.org/api/diseases/v1/MONDO_0002974/drugs?page=2